Join Perspective Therapeutics management for an in-person and virtual analyst day, featuring Richard L. Wahl, MD (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) to provide a deep dive into the use of specialized targeting peptides and personalized alpha-particle radiopharmaceuticals such as ²¹²Pb to diagnose tumors and deliver powerful radiation specifically to cancer cells.

The event will highlight the company’s theranostic approach and proprietary technology, including the development of complementary imaging diagnostics that enable the ability to see the specific tumor and then treat it, to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. In addition, company management will discuss Fibroblast Activation Protein (FAP) as its next radiotherapy target.

A live question and answer session will follow the formal presentations.